The World Health Organization (WHO) study found that the antiviral drug'remdesivir' of the US pharmaceutical company Gilead Sciences has little effect on patients with COVID-19.



Remdesivir is also known as a treatment that was administered by US President Trump, who was diagnosed with Corona 19 on the 2nd (local time).



In a'solidarity experiment' conducted by the WHO with 11,266 hospitalized patients, Remdesivir failed to reduce the length of hospitalization or lower mortality, Reuters reported on the 15th.



WHO's joint trial is a multinational clinical trial to verify the efficacy and safety of candidates for COVID-19 treatment.In addition to remdesivir, hydroxychloroquine for malaria treatment, lopinavir/ritonavir, and anti-human immunodeficiency virus (HIV) treatment. It is being conducted for viral interferon, etc.



However, the study found that among these candidates, there was no COVID-19 treatment that significantly affects the survival of inpatients with COVID-19, the news agency said.



Hydroxychloroquine and lopinavir/ritonavir had already been shown to be ineffective in June, according to WHO chief scientist Sumya Swaminatan, and solidarity tests for the remaining candidates were conducted in more than 500 hospitals in 30 countries.



Gilead Sciences said earlier this month that remdesivir shortened the recovery period by 5 days as a result of conducting a clinical trial on 1,62 hospitalized patients with Corona 19.



The research results were published in the medical journal'New England Journal of Medicin' (NEJM).



Meanwhile, in Korea, quarantine authorities have said that remdesivir was administered to 600 patients in 62 hospitals by the 13th.